Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Insmed"


5 mentions found


Here are Wells Fargo's top trades for the second quarter
  + stars: | 2024-04-02 | by ( Samantha Subin | ) www.cnbc.com   time to read: +3 min
The second quarter is underway, and Wells Fargo has laid out its top stock ideas to maximize investor returns during the period. Here are some of Wells Fargo's top names for the next three months: Wells Fargo is bullish on Amazon , naming the stock as an overweight tactical idea. Wells Fargo's $211 price target implies about 17% upside from Tuesday's close. Despite a difficult start to the year that saw shares slump about 5%, Wells Fargo anticipates about 15% upside in store for the coffee chain retailer. Wells Fargo named Tesla among its four underweight ideas for the quarter, citing slowing delivery growth and dwindling demand.
Persons: Wells, Stocks, Ken Gawrelski, Wells Fargo's, INSM, Tiago Fauth, Zack Fadem, Colin Langan's Organizations: Insmed, Starbucks, Citigroup, Devon Energy Locations: Wells Fargo, Wells, North America, Monday's
After a strong first half for the stock market, Credit Suisse has an idea to keep the gains going. Now, questions swirl around if the market can continue its ascent as the second half of 2023 kicks into high gear. Credit Suisse asked every one of its U.S. research analysts to name their top stock picks when looking at the next six to 12 months. His price target implies shares could rally nearly 35% over the next year. International Game Technology also made the list, with analyst Ben Chaiken expecting big upside ahead even after a strong first half.
Persons: Stocks, Alcoa, Curt Woodworth, Woodworth, Refinitiv, Ben Chaiken, Judah Frommer, Frommer, MasTec, Jamie Cook, — CNBC's Michael Bloom Organizations: Credit Suisse, Nasdaq, Technology
Analysts at Bank of America named five stocks this week that they say every investor must own heading into 2023. CNBC Pro combed through Bank of America research looking for stocks with major upside potential. Netflix Shares of Netflix are down 46.8% this year, but analyst Jessica Reif Ehrlich is standing by the streaming giant. Kroger Kroger shares have gained nearly 2.6% this year, but the stock has a lot more room to run, according to analyst Robert Ohmes. ... We rate Solo Brands' shares Buy as we believe its unique platform strategy should enable its high growth Leisure brands."
This biotech stock can jump more than 90%, Barclays says
  + stars: | 2022-12-08 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Little-known Insmed could take off as one of its drugs with conditional approval and another in development show promise, according to Barclays. Analyst Leon Wang initiated the stock as overweight with a price target of $37, which presents a 94.9% upside from Wednesday's close. The company focuses on pulmonology-focused commercial biotech, with two major medications for bronchiectasis, which is when airways in lungs are widened, and a lung disease. Assuming strong data out of the third trial, Wang said the medication could hit the market in 2025. He said Insmed will likely surpass sales guidance, which was already set for a 30% year-over-year increase, in 2022.
Here are Wall Street's biggest calls on Thursday: Bank of America reiterates Chevron as buy Bank of America said it's standing by its buy rating on the oil and gas giant after it announced its 2023 capital budget on Wednesday. JPMorgan upgrades Vulcan Materials to overweight from neutral JPMorgan said risks for the construction materials company are already priced in. UBS initiates Shopify as sell UBS said it's concerned about increasing competition. UBS upgrades Hershey to buy from neutral UBS said it's becoming bullish on the chocolate and candy maker's long-term growth. Bank of America reiterates Lowe's as buy Bank of America said shares of Lowe's remain attractive.
Total: 5